In the United States, Avzivi® is indicated for the treatment of 1) Metastatic colorectal cancer, 2) non-squamous non-small cell lung cancer, 3) glioblastoma in adults, 4) Metastatic renal cell carcinoma, 5) cervical cancer, 6) Epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In the Europe, Avzivi® is indicated for the treatment of 1) Metastatic carcinoma of the colon or rectum, 2) Metastatic breast cancer, 3) non-small cell lung cancer, 4) renal cell cancer, 5) epithelial ovarian, fallopian tube, or primary peritoneal cancer, 6) carcinoma of the cervix.
